Eltrombopag, also known as SB-497115-GR, is an agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was initially approved in 2008, for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulin therapy, or splenectomy. In preclinical studies, Eltrombopag was shown to interact selectively with the thrombopoietin receptor, leading to activation of the JAK-STAT signaling pathway and increased proliferation and differentiation of megakaryocytes.
Preparation process of an agonist of the thrombopoietin receptor; Bartra Sanmarti, Marti; Solsona Rocabert, Joan Gabriel; Cruces Colado, Jacobo; Enjo Babio, Juan; Pampin Casal, Maria Begona; Assignee Esteve Quimica, S.A., Spain; Galchimia, S.L. 2014; Patent Information; Nov 05, 2014; EP 2799425 A1
Preparation method of eltrombopag as thrombopoietin receptor agonist; Sun, Tingting; 2018; Patent Information; Apr 17, 2018; CN 107915677 A
Upadhye, Bhargav Krishnaji; Jagadale, Shivaji Eknath; Soni, Mukesh. Process for preparation of substituted 3'-hydrazinobiphenyl-3-carboxylic acid derivatives such as eltrombopag. Assignee Glenmark Generics Limited, India. IN 2011MU02570. (2013).
Avdagic, Amir; Baran, Phil S. Processe for the preparation of substituted biphenylcarboxylic acid compounds useful for the synthesis of eltrombopag. Assignee Assia Chemical Industries Ltd., Israel; Teva Pharmaceutical USA, Inc. WO 2013049605. (2013).
Xu, Jun; Jiang, Xinyi; Zhang, Minhua; Zhou, Yu; Xu, Meng. Preparation method of eltrombopag. Assignee ABA Chemicals (Shanghai) Ltd., Peop. Rep. China. CN 109096195. (2018).
Ji, Minghua; Shao, Dong; Liu, Yuanrui; He, Chengjiang; Wang, Qi; Wang, Lichun; Wang, Jingyi. Method for preparing Eltrombopag. Assignee Suzhou Kelun Pharmaceutical Research Co., Ltd., Peop. Rep. China; Sichuan Kelun Pharmaceutical Research Co., Ltd. CN 108101845. (2018).
